Why these ASX growth shares could rise 30%+

Analysts think these shares are undervalued. Let's see what they are saying.

| More on:
A man sees some good news on his phone and gives a little cheer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you have a penchant for ASX growth shares like I do, then read on!

That's because the two in this article have not only been named as buys but have been tipped to rise at least 30% from current levels. Here's what analysts are saying about them:

Life360 Inc (ASX: 360)

The team at Goldman Sachs thinks that this location technology company could be a quality ASX growth share to buy now.

It has a buy rating and $27.00 price target on its shares. This suggests that upside of 30% is possible for investors between now and this time next year.

The broker likes Life360 due to its huge total addressable market (TAM) and significant user monetisation opportunity. It explains:

We estimate Life360 is exposed to a US$12bn global TAM with a large opportunity to expand its product suite, grow average revenue per paying circle (ARPPC), increase payer conversion, and lift penetration rates outside of the US. The company has demonstrated its pricing power and is now exploring the latent monetisation opportunity of its >60mn user base via advertising.

Goldman also highlights that its shares are undervalued compared to peers. It adds:

 Life360's Subscription business currently trades at a discount to global subscription app peers when adjusting for its superior growth outlook. We see scope for re-rating as Life360 demonstrates operating leverage, ongoing subscription growth and user monetisation via ads. We are Buy rated on Life360.

Pro Medicus Limited (ASX: PME)

Bell Potter thinks that this health imaging technology company could be an ASX growth share to buy.

Its analysts have put a buy rating and $280.00 price target on its shares. Based on its current share price, this implies potential upside of 33% over the next 12 months.

Commenting on the company, the broker said:

Pro medicus is a leading health imaging IT provider. It's leading product is the Visage 7 Enterprise Viewer (the Visage Viewer). It is an essential component of a modern PACS with its main advantage being speed. Using this system the radiologist is able to view medical images from all major modalities at lightning fast speed including prior exams.

Visage 7 is the fastest, most versatile viewing software on the market and it is the key reason why Pro medicus has been successful in winning numerous high profile hospital contracts in the US, ahead of some of the largest global names in the industry.

Motley Fool contributor James Mickleboro has positions in Life360 and Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Life360. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Growth Shares

3 fantastic ASX growth shares to buy with $2,000 in May

Analysts think these shares would be top picks for growth investors right now.

Read more »

A man points at a paper as he holds an alarm clock.
Growth Shares

3 ASX 200 stocks to buy and hold forever without thinking twice

Here's why these shares could be great buy and hold options for investors.

Read more »

A person with a round-mouthed expression clutches a device screen and looks shocked and surprised.
Growth Shares

3 unstoppable ASX growth shares to buy and hold for the long term

Analysts have good things to say about these top stocks.

Read more »

A woman wearing dark clothing and sporting a few tattoos and piercings holds a phone and a takeaway coffee cup as she strolls under the Sydney Harbour Bridge which looms in the background.
Growth Shares

Top Australian stocks for a $7,000 investment today

These stocks are highly rated by analysts. Let's find out why.

Read more »

Two doctors give the thumbs up to an x-ray
Growth Shares

Down 9% in a month! The ASX200 growth stock I'm watching

This healthcare stock could be a buy low option. 

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Growth Shares

Invest $10,000 in these fantastic ASX growth shares

Analysts believe that these shares could be in the buy zone right now.

Read more »

Business man at desk looking out window with his arms behind his head at a view of the city and stock trends overlay.
Growth Shares

Where to invest $20,000 into ASX 200 shares after the market selloff

Analysts think these shares would be top picks for investors with money to put into the market.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Growth Shares

Now could be a golden opportunity to buy these ASX 200 growth shares

Analysts think these shares could deliver big returns over the next 12 months.

Read more »